Long-acting injectable antipsychotics for the prevention of relapse in patients with recent-onset psychotic disorders: A systematic review and meta-analysis of randomized controlled trials

Psychiatry Research

Volumn 246, Issue , 2016, Pages 750-755

  Kishi, Taro ^a   Oya, Kazuto ^a   Iwata, Nakao ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Long acting injectable antipsychotics; Meta analysis; Recent onset psychotic disorders; Relapse rate; Systematic review

Indexed keywords

NEUROLEPTIC AGENT; PALIPERIDONE; RISPERIDONE;

ADVERSE OUTCOME; AKATHISIA; AMENORRHEA; ARTICLE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; EFFECT SIZE; ERECTILE DYSFUNCTION; GALACTORRHEA; HEADACHE; HUMAN; INCIDENCE; INSOMNIA; META ANALYSIS; MORTALITY; MOTOR DYSFUNCTION; NUMBERS NEEDED TO TREAT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; RESTLESSNESS; RHINOPHARYNGITIS; RISK FACTOR; SUICIDAL IDEATION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT REFUSAL; TREMOR; ADMINISTRATION AND DOSAGE; DELAYED RELEASE FORMULATION; PHARMACOLOGY; SCHIZOPHRENIA; SECONDARY PREVENTION; STATISTICS AND NUMERICAL DATA;

ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; HUMANS; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SECONDARY PREVENTION;

EID: 85006280108     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2016.10.053     Document Type: Article

References (36)

1. Acosta, F.J., Ramallo-Farina, Y., Bosch, E., Mayans, T., Rodriguez, C.J., Caravaca, A., Antipsychotic treatment dosing profile in patients with schizophrenia evaluated with electronic monitoring (MEMS(R)). Schizophr. Res. 146:1–3 (2013), 196–200.
2. Alvarez-Jimenez, M., Priede, A., Hetrick, S.E., Bendall, S., Killackey, E., Parker, A.G., McGorry, P.D., Gleeson, J.F., Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr. Res. 139:1–3 (2012), 116–128.
3. Bartzokis, G., Lu, P.H., Amar, C.P., Raven, E.P., Detore, N.R., Altshuler, L.L., Mintz, J., Ventura, J., Casaus, L.R., Luo, J.S., Subotnik, K.L., Nuechterlein, K.H., Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory. Schizophr. Res. 132:1 (2011), 35–41.
4. Brain, C., Sameby, B., Allerby, K., Quinlan, P., Joas, E., Lindstrom, E., Burns, T., Waern, M., Stigma, discrimination and medication adherence in schizophrenia: results from the Swedish COAST study. Psychiatry Res. 220:3 (2014), 811–817.
5. Brissos, S., Veguilla, M.R., Taylor, D., Balanza-Martinez, V., The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther. Adv. Psychopharmacol. 4:5 (2014), 198–219.
6. Button, K.S., Ioannidis, J.P., Mokrysz, C., Nosek, B.A., Flint, J., Robinson, E.S., Munafo, M.R., Power failure: why small sample size undermines the reliability of neuroscience. Nat. Rev. Neurosci. 14:5 (2013), 365–376.
7. Byerly, M.J., Nakonezny, P.A., Lescouflair, E., Antipsychotic medication adherence in schizophrenia. Psychiatr. Clin. N. Am. 30:3 (2007), 437–452.
8. De la Gandara, J., San Molina, L., Rubio, G., Rodriguez-Morales, A., Hidalgo Borrajo, R., Buron, J.A., Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the SPHERE Study. Expert Rev. Neurother. 9:10 (2009), 1463–1474.
9. Emsley, R., Chiliza, B., Asmal, L., The evidence for illness progression after relapse in schizophrenia. Schizophr. Res. 148:1–3 (2013), 117–121.
10. Haddad, P.M., Kishimoto, T., Correll, C.U., Kane, J.M., Ambiguous findings concerning potential advantages of depot antipsychotics: in search of clinical relevance. Curr. Opin. Psychiatry 28:3 (2015), 216–221.
11. Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W.F., Thibaut, F., Moller, H.J., World Federation of Societies of Biological Psychiatry Task Force on Treatment Guidelines for Schizophrenia, World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J. Biol. Psychiatry 14:1 (2013), 2–44.
12. Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W.F., Thibaut, F., Moller, H.J., World Federation of Societies of Biological Psychiatry Task Force on Treatment Guidelines for Schizophrenia, World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J. Biol. Psychiatry 13:5 (2012), 318–378.
13. Higgins, J., Green, S.J., 2011. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 The Cochrane Collaboration 〈 www.cochrane-handbook.org〉.
14. Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ 327:7414 (2003), 557–560.
15. Kay, S.R., Opler, L.A., Lindenmayer, J.P., The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br. J. Psychiatry Suppl. 7 (1989), 59–67.
16. Kirschner, M., Theodoridou, A., Fusar-Poli, P., Kaiser, S., Jager, M., Patients' and clinicians' attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis. Ther. Adv. Psychopharmacol. 3:2 (2013), 89–99.
17. Kishimoto, T., Robenzadeh, A., Leucht, C., Leucht, S., Watanabe, K., Mimura, M., Borenstein, M., Kane, J.M., Correll, C.U., Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr. Bull. 40:1 (2014), 192–213.
18. Leucht, S., Corves, C., Arbter, D., Engel, R.R., Li, C., Davis, J.M., Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:9657 (2009), 31–41.
19. Leucht, S., Komossa, K., Rummel-Kluge, C., Corves, C., Hunger, H., Schmid, F., Asenjo Lobos, C., Schwarz, S., Davis, J.M., A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am. J. Psychiatry 166:2 (2009), 152–163.
20. Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Davis, J.M., Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst. Rev., 2012, 5.
21. Malla, A., Chue, P., Jordan, G., Stip, E., Koczerginski, D., Milliken, H., Joseph, A., Williams, R., Adams, B., Manchanda, R., Oyewumi, K., Roy, M.A., An exploratory, open-label, randomized trial comparing risperidone long-acting injectable with oral antipsychotic medication in the treatment of early psychosis. Clin. Schizophr. Relat. Psychoses 9:4 (2016), 198–208.
22. Merlo, M.C., Hofer, H., Gekle, W., Berger, G., Ventura, J., Panhuber, I., Latour, G., Marder, S.R., Risperidone, 2 mg/day vs. 4 mg/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning. J. Clin. Psychiatry 63:10 (2002), 885–891.
23. Messias, E.L., Chen, C.Y., Eaton, W.W., Epidemiology of schizophrenia: review of findings and myths. Psychiatr. Clin. N. Am. 30:3 (2007), 323–338.
24. Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Group, P., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ, 339, 2009, b2535.
25. NICE, 2014. Psychosis and Schizophrenia in Adults: Treatment and Management: Updated Edition 2014, London.
26. Oosthuizen, P., Emsley, R., Jadri Turner, H., Keyter, N., A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis. Int. J. Neuropsychopharmacol. 7:2 (2004), 125–131.
27. Patel, M.X., Haddad, P.M., Chaudhry, I.B., McLoughlin, S., Husain, N., David, A.S., Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years. J. Psychopharmacol. 24:10 (2010), 1473–1482.
28. Robinson, D., Woerner, M.G., Alvir, J.M., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., Lieberman, J.A., Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch. Gen. Psychiatry 56:3 (1999), 241–247.
29. Robinson, D.G., Woerner, M.G., Alvir, J.M., Bilder, R.M., Hinrichsen, G.A., Lieberman, J.A., Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr. Res. 57:2–3 (2002), 209–219.
30. Robinson, D.G., Woerner, M.G., Delman, H.M., Kane, J.M., Pharmacological treatments for first-episode schizophrenia. Schizophr. Bull. 31:3 (2005), 705–722.
31. Schreiner, A., Aadamsoo, K., Altamura, A.C., Franco, M., Gorwood, P., Neznanov, N.G., Schronen, J., Ucok, A., Zink, M., Janik, A., Cherubin, P., Lahaye, M., Hargarter, L., Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophr. Res. 169:1–3 (2015), 393–399.
32. Sham, P.C., MacLean, C.J., Kendler, K.S., A typological model of schizophrenia based on age at onset, sex and familial morbidity. Acta Psychiatr. Scand. 89:2 (1994), 135–141.
33. Spanarello, S., La Ferla, T., The pharmacokinetics of long-acting antipsychotic medications. Curr. Clin. Pharmacol. 9:3 (2014), 310–317.
34. Subotnik, K.L., Casaus, L.R., Ventura, J., Luo, J.S., Hellemann, G.S., Gretchen-Doorly, D., Marder, S., Nuechterlein, K.H., Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A randomized clinical trial. JAMA Psychiatry 72:8 (2015), 822–829.
35. Weiden, P.J., Schooler, N.R., Weedon, J.C., Elmouchtari, A., Sunakawa, A., Goldfinger, S.M., A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. J. Clin. Psychiatry 70:10 (2009), 1397–1406.
36. Whiteford, H.A., Degenhardt, L., Rehm, J., Baxter, A.J., Ferrari, A.J., Erskine, H.E., Charlson, F.J., Norman, R.E., Flaxman, A.D., Johns, N., Burstein, R., Murray, C.J., Vos, T., Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 382:9904 (2013), 1575–1586.